Aptar enters exclusive negotiations to buy Voluntis
CRYSTAL LAKE -- AptarGroup Inc. Tuesday said it has entered into exclusive negotiations for the potential acquisition of all outstanding shares of Voluntis, a pioneer in digital therapeutics.
Founded in 2001, Voluntis employs over 75 people at its offices in Paris and Boston, and would continue to operate from these locations.
This acquisition would complement Aptar's existing digital health portfolio of connected devices by adding digital therapeutic solutions, broadening its digital health services across multiple chronic conditions and diseases, the company said. Aptar specializes in drug delivery, consumer product dispensing and active material science solutions.
Voluntis's proprietary Theraxium platform supports patients in the management of their treatment in collaboration with their health care providers. The platform offers real-time decision support (e.g. for self-management of symptoms, dosing and adherence) for a wide range of chronic diseases.
Under the proposal, Aptar would acquire from certain members of the management and certain shareholders approximately 64.6% of the company.
"Voluntis has established itself as a true innovator in digital therapeutics over the last decade with chronic disease management at the core of their offering," said Stephan B. Tanda, Aptar president and CEO said.